Overview

A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During, and Post-semaglutide Therapy

Status:
RECRUITING

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass. The purpose of this study is to investigate the effect of ACM-001.1 (the study drug) on how much muscle is lost when a person takes it with semaglutide and how much muscle mass is gained when a person continues taking ACM-001.1 but stops taking semaglutide.

Phase:

PHASE2

Details

Lead Sponsor:

Actimed Therapeutics Ltd

Collaborator:

SCIRENT Clinical Research and Science d.o.o.

Treatments:

semaglutide